Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype

Journal of Magnetic Resonance Imaging

Volumn 26, Issue 6, 2007, Pages 1405-1412

  Jenkinson, Michael D ^a,b,e   Smith, Trevor S ^a   Brodbelt, Andrew R ^a   Joyce, Kathy A ^c   Warnke, Peter C ^d   Walker, Carol ^b,c  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CLATTERBRIDGE HOSPITAL   (United Kingdom)

^d LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

^e Clinical Science Centre   (United Kingdom)

Author keywords

1p 19q; ADC; DWI; Genotype; Oligodendroglioma; Ollgoastrocytoma

Indexed keywords

CHOLINE; CREATINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASTROCYTOMA; BLOOD VOLUME; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EDEMA; GENOTYPE; HUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AGED; ALLELIC IMBALANCE; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; STATISTICS, NONPARAMETRIC;

EID: 37049023877     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21062     Document Type: Article

References (43)

1. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-830.
2. Fallon KB, Palmer CA, Roth KA, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-322.
3. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-130.
4. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.
5. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-645.
6. Van Den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-1284.
7. Walker C, du Plessis DG, Joyce KA, et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 2005;57:855-865.
8. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006;66:1661-1667.
9. Mukasa A, Ueki K, Ge X, et al. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 2004;14:34-42.
10. Palfi S, Swanson KR, De Bouard S, et al. Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer 2004;91:745-752.
11. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303-4306.
12. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129(Pt 7):1884-1891.
13. Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703-713.
14. Walker C, du Plessis DG, Fildes D, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 2004;10:7182-7191.
15. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-2036.
16. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215-226.
17. Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081-1088.
18. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60.
19. Le Bihan D. Molecular diffusion nuclear magnetic resonance imaging. Magn Reson Q 1991;7:1-30.
20. Kauppinen RA. Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 2002;15:6-17.
21. Chiang IC, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004;46:619-627.
22. Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002;44:656-666.
23. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201-209.
24. Jager HR, Waldman AD, Benton C, Fox N, Rees J. Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted. and serial volumetric MR imaging. AJNR Am J Neuroradiol 2005;26:274-278.
25. Tozer DJ, Jager HR, Danchaivijitr N, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20:49-57.
26. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085-2089.
27. Kleihues P, Cavanee W. Pathology and genetics of tumors of the nervous system. In: Kleihues P, Cavanee WK, editors. World Health Organization classification of tumours. Lyon: IARC Press; 2000;55-69.
28. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004;10:7852-7859.
29. Castillo M, Smith JK, Kwock L, Wilber K. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60-64.
30. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG, 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11(Pt 1):8600-8605.
31. Dong ZQ, Pang JC, Tong CY, Zhou LF, Ng HK. Clonality of oligoastrocytomas. Hum Pathol 2002;33:528-535.
32. Walker C, du Plessis DG, Joyce KA, et al. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 2003;9:4841-4851.
33. Walker C, Joyce K, Du Plessis D, Machell Y, Sibson DR, Broome J. Molecular genetic analysis of archival gliomas using diagnostic smears. Neuropathol Appl Neurobiol 2000;26:441-447.
34. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
35. Steens SC, Admiraal-Behloul F, Schaap JA, et al. Reproducibility of brain ADC histograms. Eur Radiol 2004;14:425-430.
36. Oh J, Cha S, Aiken AH, et al. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging 2005;21:701-708.
37. Gavin CM, Smith CJ, Emsley HC, et al. Reliability of a semi-automated technique of cerebral infarct volume measurement with CT. Cerebrovasc Dis 2004;18:220-226.
38. Bilgili Y, Unal B. Effect of region of interest on interobserver variance in apparent diffusion coefficient measures. AJNR Am J Neuroradiol 2004;25:108-111.
39. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803.
40. Lev MH, Vedolin L. Permeability versus cerebral blood volume measurement in brain tumor evaluation: comparative clinical value and advice to authors. AJNR Am J Neuroradiol 2006;27:418-419.
41. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006;239:632-649.
42. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [Corrected]. AJNR Am J Neuroradiol 2004;25:214-221.
43. Wilken B, Dechent P, Herms J, et al. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol 2000;23:22-31.